Abstract
BackgroundHome dialysis is being increasingly promoted among patients with end-stage renal disease, but the comparative effectiveness of home hemodialysis and peritoneal dialysis is unknown.ObjectiveTo determine whether patients receiving home daily hemodialysis have reduced mortality risk compared with matched patients receiving home peritoneal dialysis.DesignThis study is an observational, propensity-matched, new-user cohort study.SettingLinked electronic data were from the United States Renal Data System (USRDS) and a large dialysis provider’s database.PatientsThe patients were adults receiving in-center hemodialysis in the USA between 2004 and 2011 and registered in the USRDS.MeasurementsBaseline comorbidities, demographics, and outcomes for both groups were ascertained from the United States Renal Data System.MethodsWe identified 3142 consecutive adult patients initiating home daily hemodialysis (≥5 days/week for ≥1.5 h/day) and matched 2688 of them by propensity score to 2688 contemporaneous US patients initiating home peritoneal dialysis. We used Cox regression to compare all-cause mortality between groups.ResultsAfter matching, the two groups were well balanced on all baseline characteristics. Mean age was 51 years, 66 % were male, 72 % were white, and 29 % had diabetes. During 10,221 patient-years of follow-up, 1493/5336 patients died. There were significantly fewer deaths among patients receiving home daily hemodialysis than those receiving peritoneal dialysis (12.7 vs 16.7 deaths per 100 patient-years, respectively; hazard ratio (HR) 0.75; 95 % CI 0.68–0.82; p < 0.001). Similar results were noted with several different analytic methods and for all pre-specified subgroups.LimitationsWe cannot exclude residual confounding in this observational study.ConclusionsHome daily hemodialysis was associated with lower mortality risk than home peritoneal dialysis.Electronic supplementary materialThe online version of this article (doi:10.1186/s40697-016-0105-x) contains supplementary material, which is available to authorized users.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
